This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights PepsiCo, Verizon Communications, Sanofi, Vale and Paychex
by Zacks Equity Research
PepsiCo, Verizon Communications, Sanofi, Vale and Paychex are part of the Zacks top Analyst Blog.
J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.
Top Research Reports for PepsiCo, Verizon Communications & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), Verizon Communications Inc. (VZ) and The Sanofi (SNY).
J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study
by Zacks Equity Research
J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.
Sanofi (SNY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed the most recent trading day at $49.83, moving +1.14% from the previous trading session.
Encompass Health's (EHC) Plan Marks Entry in Rhode Island
by Zacks Equity Research
Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.
SNY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
State of California Sues Insulin Makers for Unfair Practices
by Zacks Equity Research
The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
by Zacks Equity Research
Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
by Zacks Equity Research
Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.
Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update
by Zacks Equity Research
Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.
AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B
by Zacks Equity Research
AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.
Sanofi (SNY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed the most recent trading day at $48.51, moving +0.77% from the previous trading session.
FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.
Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day.
FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA
by Zacks Equity Research
The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
SNY or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal
by Zacks Equity Research
Data from a late-stage study shows that treatment with Pfizer's (PFE) hemophilia B gene therapy resulted in a 71% reduction in annualized bleed rate (ABR) compared to standard-of-care treatment.
TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
by Zacks Equity Research
The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.
Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance
by Zacks Equity Research
The FDA assigns a standard review to Pfizer's (PFE) BLA for pentavalent meningococcal vaccine candidate (MenABCWY), with a decision expected in October 2023.
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why
by Zacks Equity Research
Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
by Kinjel Shah
Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.